ClinicalTrials.gg
CompletedNCT02154347Updated Sep 6, 2019Results posted

Post-marketing Clinical Trial of KAD-1229 in Patients With Type 2 Diabetes Mellitus

A Phase 4 interventional study of KAD-1229 and Placebo in Type 2 Diabetes Mellitus, sponsored by Kissei Pharmaceutical Co., Ltd.. Completed at 1 site in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2019-09-06.

Sponsored by Kissei Pharmaceutical Co., Ltd. · Phase 4 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
178
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 394 studies in Diabetes Mellitus, Type 2 with a site in Japan — 23 open to participants now, 31 under way, 22 of them phase 3. Diabetes Mellitus, Type 2 · Japan.

Enrollment
218th of 334
178 · median 284
Phase 4
50 of 394
none open now
Registered
213th of 394
by date

Among the 394 studies in Diabetes Mellitus, Type 2 with a site in Japan, this one is the 218th largest by enrollment of the 334 interventional ones that give a count, is one of 50 in phase 4, and was the 213th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

23 of the 394 studies in Diabetes Mellitus, Type 2 with a site in Japan are open now. Recruiting first, the newest first:

18 more — sign in →

All 23 open studies →

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 20 Years and older · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 394 studies in Diabetes Mellitus, Type 2 with a site in Japan, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and efficacy of KAD-1229 as combination therapy with insulin for 16 weeks and up to 52 weeks administration in patients with type 2 Diabetes Mellitus who show inadequate glycemic control with diet, and insulin monotherapy, or insulin and oral hypoglycemic agent.

03

Conditions studied

  • Type 2 Diabetes Mellitus

Keywords

  • Type 2 Diabetes Mellitus
  • HbA1c
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients who has been receiving dietary therapy and a stable dose and regimen of insulin over 8 weeks before at the time of an observation term start
  • Patients whose at the time of an observation term start is 7.5% or more and less than 10.0%

Exclusion criteria

Exclusion Criteria:

  • Type 1 Diabetes Mellitus
  • Patients with serious diabetic complications and other serious complications
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 4
Enrollment
178 participants (actual)

Study arms

  • Experimental
    KAD-1229/KAD-1229

    Patients are administered KAD-1229 for 16 weeks (double-blind period), followed by KAD-1229 for up to 52 weeks (open-label period) with insulin throughout the study.

    Drug: KAD-1229 · Drug: Insulin

  • Other
    Placebo/KAD-1229

    Patients are administered Placebo for 16 weeks (double-blind period), followed by KAD-1229 for up to 52 weeks (open-label period) with Insulin throughout the study.

    Drug: KAD-1229 · Drug: Placebo · Drug: Insulin

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline in HbA1c

    Time frame: 16 weeks

07

Results

Posted Sep 6, 2019

Participant flow

Double-blind Period
Participant flow — Double-blind Period
MilestonePlacebo/KAD-1229KAD-1229/KAD-1229
Started60118
Completed57114
Not completed34
Withdrew: Adverse event12
Withdrew: Lack of efficacy10
Withdrew: Physician decision01
Withdrew: Withdrawal by subject11
Open-label Period
Participant flow — Open-label Period
MilestonePlacebo/KAD-1229KAD-1229/KAD-1229
Started57113
Completed5088
Not completed725
Withdrew: Adverse event34
Withdrew: Lack of efficacy419
Withdrew: Protocol violation01
Withdrew: Withdrawal by subject01

Outcome measures

PrimaryChange From Baseline in HbA1c
Time frame:
16 weeks
Reported as:
Mean · % (value of HbA1c)
Change From Baseline in HbA1c
% (value of HbA1c)Placebo/KAD-1229KAD-1229/KAD-1229
Change From Baseline in HbA1c0.05 ± 1.04-0.61 ± 0.87
Statistical analysis
  • Placebo/KAD-1229 vs KAD-1229/KAD-1229 · t-test, 2 sided · p = <0.001 · Mean difference (final values): -0.66 · 95% CI -0.95 to -0.37

Adverse events

Collected over Placebo/KAD-1229 and KAD-1229/KAD-1229: 16 weeks, KAD-1229: 52 weeks. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo/KAD-1229 (Data Through Week 16)0/60 (0%)2/60 (3.3%)19/60 (31.7%)
KAD-1229/KAD-1229 (Data Through Week 16)0/118 (0%)4/118 (3.4%)28/118 (23.7%)
KAD-1229 (Data Through Week 52)0/175 (0%)18/175 (10.3%)98/175 (56%)
Most frequent serious events
Showing 10 of 18
Most frequent serious events
EventPlacebo/KAD-1229 (Data Through Week 16)KAD-1229/KAD-1229 (Data Through Week 16)KAD-1229 (Data Through Week 52)
Angina pectorisCardiac disorders0/601/1183/175
Myocardial ischaemiaCardiac disorders1/600/1181/175
Pneumonia bacterialInfections and infestations1/600/1180/175
Sick sinus syndromeCardiac disorders1/600/1180/175
Colon cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/601/1181/175
Metastases to liverNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/601/1181/175
Pancreatic carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/601/1181/175
Angina unstableCardiac disorders0/601/1181/175
PneumoniaInfections and infestations0/600/1181/175
Renal cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/600/1181/175
Most frequent other events
Showing 10 of 17
Most frequent other events
EventPlacebo/KAD-1229 (Data Through Week 16)KAD-1229/KAD-1229 (Data Through Week 16)KAD-1229 (Data Through Week 52)
NasopharyngitisInfections and infestations10/6013/11849/175
Cold sweatSkin and subcutaneous tissue disorders0/602/1189/175
HungerGeneral disorders1/602/1189/175
Back painMusculoskeletal and connective tissue disorders3/603/1186/175
AstheniaGeneral disorders2/602/1188/175
DizzinessNervous system disorders1/603/1188/175
Blood triglycerides increasedInvestigations1/602/1188/175
HypoglycaemiaMetabolism and nutrition disorders2/601/1186/175
PalpitationsCardiac disorders0/602/1186/175
BronchitisInfections and infestations0/600/1186/175

Baseline characteristics

Age, Continuous
Age, Continuous(years)Placebo/KAD-1229KAD-1229/KAD-1229Total
Mean56.5 ± 11.759.7 ± 10.358.6 ± 10.9
Sex: Female, Male
Sex: Female, Male(Participants)Placebo/KAD-1229KAD-1229/KAD-1229Total
Female93948
Male5179130
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo/KAD-1229KAD-1229/KAD-1229Total
American Indian or Alaska Native000
Asian60118178
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported000
HbA1c
HbA1c(%)Placebo/KAD-1229KAD-1229/KAD-1229Total
Mean8.54 ± 0.858.48 ± 0.708.50 ± 0.75
08

Study locations

1 site
  • Multiple Locations, Japan
09

Timeline

Tracking since Sep 25, 2026

Results were first posted in Sep 2019, 3 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 30, 2014
First posted
Jun 3, 2014
Primary completionActual
Jul 2016
Results first posted
Sep 6, 2019
Last update
Sep 6, 2019
What these dates mean
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 6, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02154347
Responsible party
Sponsor
First posted
Jun 3, 2014
Primary completion
Jul 2016
Results posted
Sep 6, 2019
Last update
Sep 6, 2019
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mitiglinide

Start the discussion